Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006264 · ClinicalTrials.gov registry record · Phase 2
Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
A Phase 2 study of Lymphoma, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
NCT00006264: Completed Phase 2 study of Lymphoma, sponsored by AIDS Malignancy Consortium.
NCT00006264 is a Phase 2 study of Lymphoma that has completed, run by AIDS Malignancy Consortium. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006264, a Phase 2 study of Lymphoma, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Antiviral drugs such as zidovudine and ganciclovir act against viruses and may be an effective treatment for HIV. Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. Combining these treatments may be effective in treating AIDS-related primary central nervous system lymphoma. PURPOSE: Phase II trial to study the effectiveness of combining zidovudine, ganciclovir, and interleukin-2 in treating patients who have AIDS-related primary central nervous system lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL aldesleukin
- DRUG ganciclovir
- DRUG zidovudine
Study Locations (2)
Florida
- Sylvester Cancer Center, University of Miami - Miami
Ohio
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2003-07 |
| Phase | Phase 2 |
What the finished NCT00006264 record still lists
NCT00006264 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which aldesleukin is the first listed.
NCT00006264 reports a single indexed study location in Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT00006264 about?
NCT00006264 is a clinical study titled "Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma". RATIONALE: Antiviral drugs such as zidovudine and ganciclovir act against viruses and may be an effective treatment for HIV. Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. Combining these treatments may be effective in treating AIDS-related primary central nervous s...
What is the current status of trial NCT00006264?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-07. Estimated completion is 2003-07.
What conditions does trial NCT00006264 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00006264?
The interventions under investigation include: aldesleukin (BIOLOGICAL), ganciclovir (DRUG), zidovudine (DRUG).
Who is sponsoring clinical trial NCT00006264?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006264 being conducted?
This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia